Ongoing controversies about the use of calcium channel blockers (CCBs) have caused major agitations in patients and physicians' management of hypertension. The controversy about short-acting nifedipine has highlighted the inappropriate use of this agent for indications that were never approved. However, the other elements of the controversy have no scientific basis and do not in any way incriminate the appropriate use of long-acting CCBs. Prospective, controlled studies are now available documenting the safety of long-acting CCBs and additional large-scale trials are in progress.
|Original language||English (US)|
|Number of pages||6|
|Journal||Drugs of Today|
|State||Published - Dec 30 1996|
ASJC Scopus subject areas
- Pharmacology (medical)